Objective: To evaluate the influence of cyclodextrin polysulphate (CDPS) on the extracellular matrix (ECM) metabolism of human articular cartilage chondrocytes.
Introduction
Sulphated polysaccharides have been licensed for the use in different pathophysiological conditions, e.g., to modulate plasma anticoagulant and fibrinolytic activities, to exert hypolipaemic effects, to inhibit retroviral multiplication. Interestingly, most of these distinct effects are shared by different polysulphated polysaccharides.
Where degenerative joint diseases are concerned, the most interesting biological activities of these sulphated substances are their effects on synthesis and turnover of important compounds of the extracellular matrix (ECM) of connective tissues. The first reports already dated from the early 1970s 1e4 but extended reviews on the potential use of these polysaccharides have appeared more recently 5, 6 . Amongst other glycosaminoglycans, chondroitin sulphate was shown to increase aggrecan synthesis by articular cartilage cells 7 and both chondroitin sulphate and chondroitin polysulphate (CPS) increased hyaluronan synthesis by synovial lining cells in vitro 8 and in vivo 9, 10 . Interestingly, hyaluronan molecular weight significantly increased when synovial cells were treated with CPS and other sulphated polysaccharides 9e11 . Similarly, human articular chondrocytes in monolayer culture responded with an increased synthesis of highly polymerised hyaluronan when CPS was supplemented to the culture medium 12 . Under the same conditions these articular cartilage cells increased their production of aggrecans in the aggregate form 13 . Electron microscopic studies confirmed the immobilisation of higher numbers of aggrecans on longer hyaluronan filaments synthesised by differentiated human cartilage cells exposed to CPS and other sulphated polysaccharides such as xylosan polysulphate 13 . Considering their capability of increasing synthesis rates and improving the immobilisation of physiologically important ECM molecules, some of these sulphated polysaccharides have been considered to be important therapeutical tools in osteoarthritis (OA), where declining aggrecan synthesis rates and the decreased capability of assembling large molecular size aggregates illustrate the progressive failure of the repair function of articular cartilage cells. A damaged articular cartilage can affect the normal function of the joint and this ultimately results in clinical symptoms in a proportion of the patients 14 . Structure/ disease modifying OA drugs (DMOADs) are expected to prevent structural damage in normal joints at risk for development of OA, or to retard the progression of structural damage in joints already affected by OA 15 . A major flaw when these substances are introduced for pharmacological use in humans is their poor chemical definition. The exact molecular weight is varying. The degree and type of sulphation is different on each of the individual molecules. One class of biologically occurring polysaccharides with well-defined molecular structure and weight are the cyclodextrins. a-, b-and g-cyclodextrins are cyclic polysaccharides containing 6, 7 and 8 glucopyranose units, respectively, linked through a1-4 glycosidic bonds. Classical sulphation procedures result in the sulphation of the three free hydroxyl groups of the glucopyranoses.
a-, b-and g-cyclodextrins have been fully sulphated and the influence of these cyclodextrin polysulphates (CDPSs) on the ECM metabolism of human articular cartilage chondrocytes has been evaluated. The incorporation of radiosulphate in proteoglycan was used as a variable to assess which concentrations of the cyclodextrins would result in an effect on chondrocyte metabolism. Once the optimal working concentrations were defined, the effects on factors known to affect the homeostasis of the ECM by chondrocytes from intact articular cartilage were assessed in more detail.
Materials and methods

PREPARATION OF SULPHATED a-, b-, AND c-CYCLODEXTRINS
Commercially available a-, b-, and g-cyclodextrins (Sigma Chemical Company, St. Louis, USA) were sulphated according to the procedure described by Astrup et al. 16 . Briefly, drop-by-drop, one volume of chlorosulphonic acid was added to 6.6 volumes of ice-cold pyridine. Approximately, 300 mg of the polysaccharides was added to 5 ml of the chlorosulphonic/pyridine mixture. The solution was then kept at 100(C for 5 h. After cooling, 25 ml of distilled water was added. One hundred milliliters of 10% (w/v) Na-acetate in methanol was then added to this solution to precipitate the polysaccharide polysulphuric acids. The precipitate was washed two times in methanol and dissolved in an appropriate amount of distilled water before being applied to a Sephadex G10 gel permeation chromatography column to elute the remaining chlorosulphonic acid, pyridine and buffer salts. The void volume fractions containing the polysaccharides were lyophilised. The cyclodextrin polysulphates were recovered as a dry white powder. Electrophoresis on cellulose acetate in a LiCl/HCl (0.01/0.06 N) buffer pH 3.5, at 1 mA/cm kept for 20 min was done to evaluate the degree of sulphation of the cyclodextrins and showed the polysulphated cyclodextrins migrating as homogeneous bands and with the same velocity as the CPS or xylosan polysulphate standards (Fig. 1) . Mass Spectrometry was done in the Institut de Recherche SERVIER Laboratories (Orleans, France; Dr F Lefoulon) and confirmed complete sulphating of all cyclodextrin glucopyranoses. Considering initial molecular weights of 973, 1135 and 1297 Da for the unsulphated a-, b-, and g-cyclodextrins, respectively, on sulphation of the three free hydroxyl groups of the glucopyranoses their molecular weights increased to 2413, 2815 and 3217. The CDPSs were used as such in our experimental in vitro models.
ISOLATION OF ARTICULAR CHONDROCYTES
Human articular chondrocytes were isolated as described elsewhere 17 . Chondrocyte cultures in alginate beads were prepared as described elsewhere 18 , with some modifications. Chondrocytes suspended in one volume of double-concentrated Hank's Balanced Salts Solution without calcium and magnesium (HBSS; Gibco) were carefully mixed with an equal volume of 2% (w/v) alginate (low-viscosity alginate from Macrocystis pyrifera; Sigma) in HBSS, autoclaved for 15 min. The final cell concentration was 5 ! 10 6 chondrocytes/ml in 1% alginate. The chondrocyte/alginate suspension was then slowly dripped through a 23-gauge needle into a 102 mM calcium chloride solution. The beads were allowed to polymerise for 10 min at room temperature. The calcium chloride was then removed, the beads were washed three times with 0.15 M sodium chloride and finally maintained in a 6-well plate with 1 ! 10 6 cells per culture (each well containing 20 alginate beads; G50,000 chondrocytes per bead) in 4 ml of DMEM with 10% FCS and 50 mg ascorbate/ ml in an incubator at 37(C under 5% CO 2 . The nutrient medium was replaced twice weekly for 7 days. Recently, we described that ECM metabolism by chondrocytes reached steady state after 1 week in this alginate culture system 19 .
INCORPORATION OF 35 SULPHATE TO MEASURE NEWLY SYNTHESISED AGGRECANS
Incorporation of 35 Sulphate to measure newly synthesised aggrecans by chondrocytes cultured in alginate was investigated using Na 2 35 SO 4 as a radioactive precursor. As the optimal working concentrations of the oversulphated cyclodextrins were not known, chondrocytes obtained from six donors were used to test different concentrations (0.5e10.0 mg/ml) of the oversulphated cyclodextrins. The cyclodextrins were supplemented to the nutrient media during the whole culture period. After a 1-week culture period in alginate, 10 mCi/ml of the label was included in the incubation medium over 24 h. During this period, newly synthesised 35 S-aggrecans partly accumulated in the artificial matrix. The alginate was then solubilised with 3 ml of 55 mM tri-sodium citrate dihydrate pH 6.8, 0.15 M NaCl at 25(C for 10 min and suspension was centrifuged. 35 S-labelled macromolecules from the resulting supernatant were pooled with 35 S-material that had escaped to the nutrient medium, and stored for further chromatography. Aliquots of pools of combined media and alginate digests were desalted through Sephadex G25 (Pharmacia) chromatography gels in 0.067 M phosphate (K 2 HPO 4 /Na 2 HPO 4 ) pH 6.8, containing 0.01 M Na 2 SO 4 , to separate 35 S-labelled aggrecans (void volume) from free 35 Sulphate (retarded fraction). The eluted fractions were counted for radioactivity.
The radioactivity in the void volume is related to the total incorporation of 35 Sulphate in newly synthesised aggrecans by the respective cultures. Considering the amount of pooled culture medium that ultimately was analysed after chromatography, the specific activity of the incubation medium (mCi 35 SO 4 per mM cold SO 4 ), the decay of 35 Sulphate, the labelling period in hours and the numbers of cells per culture, we were able to express sulphate incorporation as picograms of SO 4 incorporated per 1 ! 10 6 chondrocytes/h 20 .
IL-6 RELEASE BY CHONDROCYTES
Chondrocytes obtained from both visually intact and fibrillated cartilage of a 69-year-old female donor who presented a focal OA lesion, were kept in culture separately, and exposed to 0.0 and 5.0 mg/ml of b-CDPS for 1 week. Additionally, normal chondrocyte cultures with and without b-cyclodextrin were exposed to 100 pg/ml of tumor necrosis factor alpha(TNFa) (R&D systems, Abingdon, UK) during the last 48 h in culture. Culture media were then assayed for interleukin-6 (IL-6) by conventional enzyme linked immunosorbent assay (ELISA).
FLOW CYTOMETRIC ASSAY OF CELL-ASSOCIATED ECM MOLECULES AND OF INTRACELLULAR CYTOKINE AND GROWTH FACTOR LEVELS
Chondrocytes obtained from three additional donors were used to test the effects of the cyclodextrins on the activity of autocrine cytokine and growth factor pathways and on the presence of cell-associated matrix (CAM) molecules. The chondrocytes were cultured in alginate and in the presence of 0.0, 2.5 and 5.0 mg/ml of CDPS for a period of 7 days after which time culture medium was removed and alginate beads processed as described above. The resulting suspension was centrifuged at 1500 rpm for 10 min to separate cells with their CAM 19, 21 from the constituents of the interterritorial matrix. The pellet with the chondrocytes was recovered to assess the CAM macromolecule contents, the plasma membrane-bound receptors and the intracellular levels of cytokines and growth factors. Insulinlike growth factor receptor-1 (IGFR1), IL-1RI and -II on the cell membrane and aggrecan, type II collagen and fibronectin in the CAM were tested directly after incubation with the appropriate antibodies for 30 min in the dark at 4(C. Twenty microliters of 50 mg/ml fluorescein isothiocyanate (FITC)-labelled antibodies were used to react with 2 ! 10 5 cells resuspended in 100 ml phosphate buffered saline (PBS). In order to evaluate the expression of IGF-1, IL-1a and -b inside the cells, cultures were incubated with monensin (GolgiStopÔ, 4 ml/6 ml medium) for 5 h to block the protein transport from Golgi apparatus. Following this, chondrocytes were permeabilized using Cytofix/Cytoperm PlusÔ Kit (PharMingen, San Diego, CA, USA) according to the manufacturer's instruction. The cells were treated with Cytofix/CytopermÔ solution for 20 min. After a wash in 1! Perm/WashÔ solution, the procedure was followed by the incubation with monoclonal antibodies (mAb). 22 . The anti-aggrecan and type II collagen mAbs were conjugated with phycoerythrin (PE, SigmaeAldrich) 23 . The conjugated mAbs were used in a direct immunofluorescent staining protocol for flow cytometry. Appropriate FITC-or PElabelled isotype matched mouse or rabbit IgG 1 (Becton Dickinson: clone X40) was used as a negative control.
FLOW CYTOMETRIC ANALYSIS
Stained cells were analysed on a flow cytometer (FACSort, Becton Dickinson, San Jose, CA, USA) with CELLQuest software. From each sample, 15,000 events were analysed. Cells were gated on forward and side scatter to exclude debris and aggregates. Propidium iodide was additionally used to exclude dead cells when the epitopes outside the cells, i.e., IGFR1, IL-1RI and -II and ECM molecules, were analysed 22, 24 . The median fluorescence intensity (MFI) of the positive cell population, which is due to the binding of the conjugated antibodies, was used to quantify the presence of IGFR1, IL-1RI and -II on the plasma membrane, of the ECM molecules in the CAM, and the accumulation of IGF-1, IL-1a and -b inside the cells. To differentiate the positive mAb-stained cells, the interface channel for positivity was set at the point where less than 2% of the control fluorescence (cells exposed to FITC/PE isotype matched IgG) was positive. MFI values of these mAb-stained chondrocyte populations were then calculated. For comparison between experiments the Quantum Simply Cellular Microbead Kit (Sigma) was used to calibrate the fluorescence scale of the flow cytometer. The product contains a mixture of four uniform microbead populations, which differ by their incremental capacities to bind mouse IgG. The microbeads were stained and processed in parallel with the cell samples using the same amount of FITC-labelled antibodies and incubation time. The fluorescence scale of the cytometer was adapted before every experiment in order to keep identical MFIs for the four peaks of the calibration beads. The MFI of cell samples was then analysed without changing any instrument settings.
STATISTICS
Mean
35 S-incorporation rates or mean MFI values for the different parameters in each of the donor chondrocytes were calculated from triplicate cell cultures. As the 35 Sincorporation experiments were done on the cells obtained from six donors, the mean 35 S-incorporation values in the untreated controls were normalised to 100 to allow percentage changes after the exposure to different concentrations of CDPS to be presented. Mean MFI values in the untreated controls were compared with these obtained after the exposure to different concentrations of CDPS. Paired Student's t tests were used to test significance and to study the effect sizes of the changes in the chondrocyte cultures after CDPS treatment. Significance levels for all tests were set at P Z 0.05.
Results
EFFECT OF DIFFERENT CONCENTRATIONS OF a-, b-AND c-CYCLODEXTRINS ON AGGRECAN SYNTHESIS RATES
Synthesis of aggrecans was investigated using Na 2 35 SO 4 as a radioactive precursor. The incorporation of SO 4 was expressed as picograms of SO 4 incorporated in aggrecan macromolecules per 1 ! 10 6 chondrocytes/h ( Table I) . As optimal doses of use of the a-, b-and g-cyclodextrins were not known, and information about any differential effects of the three cyclodextrin was lacking, broader dose ranges were used in the first two donor cells. The chondrocytes of the last four donors were used to explore effects of and/or differences between the three cyclodextrin types at the optimal concentration of 2.5e5.0 mg/ml of culture medium. a-, b-and g-cyclodextrins, used at 0.5, 1.0 and 10.0 mg/ml concentrations, failed to provoke consistent significant increases in 35 S-incorporation in aggrecan in two first donors. At concentrations ranging between 2.5 and 5.0 mg/ml, a-, b-and g-cyclodextrins significantly improved aggrecan synthesis by the chondrocytes of four other donors. Higher concentrations of the oversulphated cyclodextrin inhibited 35 S aggrecan synthesis (Table I) . In a control experiment on the cells obtained from donor F53, unsulphated cyclodextrin (Table I) . Percentage changes in 35 S-incorporation in aggrecan induced by different concentrations of the three cyclodextrins are given in Fig. 2 .
FLOW CYTOMETRIC ANALYSIS OF THE CAM CONTENT
Following the results of the dose-finding studies, bcyclodextrin at 2.5 and 5.0 mg/ml concentrations was used in flow cytometry experiments on the cells of three additional donors. When compared with controls, 2.5 mg/ml of b-CDPS-treated chondrocytes showed a significantly increased accumulation of aggrecan, type II collagen and of fibronectin in their CAM (Table II) . b-CDPS (5.0 mg/ml) in the culture medium did not cause larger effects. The effect sizes of these increases varied amongst the three donor chondrocyte populations. Some illustrative flow cytometer patterns are given in Fig. 3 .
THE IGF-1/IGFR1 AUTOCRINE PATHWAY AND IL-1RII
When compared with controls, b-CDPS did not induce any changes in plasma membrane-bound IGFR1. Intracellular IGF-1 levels also remained unchanged after exposure to the polysulphated cyclodextrin. Likewise, plasma membrane-bound decoy IL-1RII did not change under CDPS treatment (Table II) .
EFFECTS ON THE IL-1/IL-1RI AUTOCRINE PATHWAY
Membrane-bound IL-1RI did not change under CDPS treatment. However, intracellular IL-1a and b levels were found downregulated after exposure of the chondrocytes to b-or g-CDPS (Table II) . No significant differences in IL-1 repression were observed under 2.5 and 5.0 mg/ml of the cyclodextrins, which were the optimal concentrations revealed in the 35 S-incorporation experiments. Percentage decreases of both IL-1 isoforms exposed a more pronounced effect on IL-1a. The effect sizes of this inhibition also varied amongst the three donor chondrocyte populations and ranged in between 14.6% and 48.1%, and 6.0% and 22.9% of inhibition for intracellular IL-1a and -b, respectively (Table II) . The smallest change in IL-1 levels concurred with the least increase in accumulated CAM compounds. Chondrocytes from OA regions secreted 2e3 times more IL-6 in the supernatant media than cells from intact cartilage. TNFa (100 pg/ml) caused a fourfold increase in IL-6 release by normal chondrocytes in culture. b-cyclodextrin polysulfate (5 mg/ml) depressed IL-6 release by normal and OA chondrocytes to approximately 60% of the baseline values. A 25% repression of the release of IL-6 by 5.0 mg/ml b-cyclodextrin-treated TNFa-primed chondrocytes was observed (Fig. 4) .
Discussion
Catabolic cytokines, e.g., IL-1, affect the homeostasis of the ECM in normal and OA cartilage and are produced by chondrocytes themselves 25, 26 . In OA chondrocytes or cartilage, the upregulation of the catabolic IL-1a and b pathways has been reported 27, 28 and a correlation with the occurrence and the degree of OA pathology was noted for IL-1b 25, 26, 29 . Increased IL-1 release by chondrocytes has been reported to be mediated by TNFa 30 . Auto/ paracrine TNFa resulting from apoptosis of chondrocytes following excessive mechanical stress 31, 32 may thus induce an IL-1-induced destruction of the extracellular environment of articular cartilage.
Agents that possibly alter the evolution of degenerative joint disease (DMOAD) should at least demonstrate how far they affect connective tissue metabolism in suitable in vitro models. Human articular chondrocytes maintain their original phenotype and metabolic characteristics when cultured in alginate gel 18,21,33e46 . Articular cartilage cells in this culture condition synthesise cartilage-specific collagens and ECM aggrecans 33, 34 . Recently, it has been shown that chondrocytes obtained from intact tissues maintain their normal metabolism, whereas chondrocytes from OA cartilage retain their catabolic phenotype when cultured in alginate 37 . The system is suitable for the study of the effects of putative pharmaceutical agents on behaviour in vitro of human chondrocytes.
In most in vitro conditions tested so far, 35 SO 4 used by phenotypically stable cartilage cells is incorporated for the most part in aggrecan. Variations in low hydrodynamic size proteoglycans such as decorin, biglycan, fibromodulin, type XI collagen and other physiologically important but less abundant extracellular macromolecules are not studied with these approaches. Hence, the incorporation by chondrocytes of 35 Sulphate in macromolecules is commonly considered to be a variable reflecting aggrecan synthesis. Increased 35 S-incorporation would unlikely have resulted from an increase in cell numbers or from an improved sulphating of the aggrecan glycosaminoglycan chains during exposure to the b-cyclodextrins. Polysulphated polysaccharides were never shown to increase cell proliferation. In addition, no reports exist on the degree of sulphating of glycosaminoglycan chains produced by 38 . A possible increase in sulphating by b-cyclodextrin of the almost 95% sulphated glycosaminoglycan disaccharides in this experimental condition could not explain the 30e60% increases in 35 Sincorporation reported here. 35 Sulphate incorporation in aggrecan was thus used as a measure to find out the optimal working concentration with these polysulphated a-, b-and g-cyclodextrins. The alginate is an unsulphated polysaccharide and differences in levels of the added sulphated polysaccharides in media and the artificial matrix did probably not occur. Cyclodextrin doseresponse curves showed optimal effects at 2.5e5.0 mg/ml of the sulphated polysaccharides. Apparently, the three polysulphated cyclodextrins did not differently affect 35 Saggrecan synthesis. The increase in aggrecan synthesis was obvious in the chondrocytes obtained from different donors. Higher doses of the three cyclodextrins inhibited 35 S-aggrecan synthesis. These bell-shaped dose-effect curves have been previously reported when other oversulphated polysaccharides were used 13, 39, 40 . The inhibition of aggrecan synthesis at higher concentrations of the polysulphated polysaccharides in the incubation medium was not due to direct toxic effects on the chondrocytes as the cells did not stain with trypan blue when exposed to these high cyclodextrin concentrations (results not shown). Unpublished observations in this laboratory showed this inhibition to occur at even lower polysaccharide concentrations when low amounts of serum were supplemented to the nutrient media of these chondrocyte cultures. Hence, the lowered synthesis rates of ECM macromolecules could be possibly explained by the tendency of these polysulphated polysaccharides to bind to various biological agents of protein nature. This quality has been exploited in various polysaccharide polysulphate (e.g., heparin, dextransulphate)-loaded affinity chromatography columns to remove and to purify cytokines and growth factors from biological fluids 41, 42 . Polysulphated polysaccharides with different molecular structures, e.g., heparin, chondroitin sulphate, (CPS) and xylosan polysulphate, have been found to modulate connective tissue metabolism. As the exposure of connective tissue cells in culture to these polysaccharides almost invariably caused increased extracellular amounts of 35 Sproteoglycan and 3 H-glucosamine-labelled hyaluronan, it was assumed that these agents directly enhanced the synthesis rates of these ECM macromolecules 7, 8, 12, 13 . Our present findings, however, reveal a new paradigm by which increased synthesis rates of aggrecan could have resulted from a repression of an autocrine chondrocyte IL-1 pathway as IL-1 is known to decrease the synthesis of aggrecan via nitric oxide (NO) 43, 44 . Some of these polysulphated saccharides have been shown to directly inhibit 45e50 , or to slow down the production 51, 52 of a variety of enzymes that are capable of digesting important ECM compounds. Our finding that these polysulphated cyclodextrins decreased IL-1a and -b levels inside the cells supports their anticatabolic activities. These intracellular cytokines represent a reservoir of biologically active agents, of which variable amounts are secreted as a result of various stimuli. It can be anticipated that the intracellular amounts of these bioactive molecules predict their extracellular function. Obviously, the inhibition of these auto/paracrine catabolic pathways was followed by a significantly increased accumulation of CAM aggrecan, type II collagen and fibronectin.
The fact that b-CDPS interferes with chondrocyte IL-1 was further exemplified by the effects on IL-6 release in the incubation media. Considering the role of auto/paracrine IL-1 pathways in the secretion of IL-6 by articular cartilage cells 53, 54 , we studied the release of IL-6 as an IL-1-dependent variable by chondrocytes obtained from both normal and OA cartilages. We found that OA cells secreted significantly more IL-6 than normal chondrocytes, illustrating the well-documented increase of auto/paracrine IL-1 activity in OA chondrocytes. b-CDPS inhibited the synthesis of IL-6 in both normal and OA chondrocytes. Although the experiments were not performed in the presence of IL-1-blocking antibodies, it is supposed that b-cyclodextrin affected the IL-1 loop and did not directly impede the production of IL-6.
Furthermore, b-CDPS inhibited the release of IL-6 by TNFa-primed chondrocytes. Although a possible downmodulation of TNF effects by b-cyclodextrin was not excluded in these experiments, we postulate that the impaired IL-6 release could have been obtained through an interference with IL-1.
It is as yet speculative to defend the use of oversulphated cyclodextrins to protect cartilage in clinical conditions such as OA. The effects, however, of these agents on articular cartilage cell metabolism illustrate their 'structure modifying effects' on connective tissues and may predict their properties as DMOAD. 893 Osteoarthritis and Cartilage Vol. 13, No. 10 
